Ensysce Biosciences, Inc. (ENSC)

Market Cap	5.05M
Revenue (ttm)	6.22M
Net Income (ttm)	-6.82M
Shares Out	2.37M
EPS (ttm)	-7.15
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	216,328
Open	2.210
Previous Close	2.160
Day's Range	2.130 - 2.300
52-Week Range	1.620 - 14.670
Beta	0.99
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2025

About ENSC

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company’s lead product candidate is PF614, a TAAP oxycodone prodrug candidate for the...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 8
• Stock Exchange: NASDAQ
• Ticker Symbol: ENSC
• Website: https://www.ensysce.com

Financial Performance

In 2024, Ensysce Biosciences's revenue was $5.21 million, an increase of 133.58% compared to the previous year's $2.23 million. Losses were -$7.99 million, -24.83% less than in 2023.